Your browser doesn't support javascript.
loading
Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.
Bibeau, K; Pandya, A G; Ezzedine, K; Jones, H; Gao, J; Lindley, A; Harris, J E.
Afiliação
  • Bibeau K; Incyte Corporation, Wilmington, Delaware, USA.
  • Pandya AG; Palo Alto Foundation Medical Group, Sunnyvale, California, USA.
  • Ezzedine K; University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Jones H; Department of Dermatology, Henri Mondor University Hospital and Université Paris-Est Créteil Val de Marne, Paris, France.
  • Gao J; Incyte Corporation, Wilmington, Delaware, USA.
  • Lindley A; Incyte Corporation, Wilmington, Delaware, USA.
  • Harris JE; Incyte Corporation, Wilmington, Delaware, USA.
J Eur Acad Dermatol Venereol ; 36(10): 1831-1844, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35611638
ABSTRACT

BACKGROUND:

Vitiligo, an autoimmune disorder characterised by skin depigmentation, is associated with reduced quality of life (QoL). Vitiligo may be under-reported, in part because of misconceptions that it is a cosmetic disease.

OBJECTIVES:

This survey sought to characterise vitiligo prevalence and explore the relationship between sociodemographic and clinical characteristics with QoL in a population-based, multinational study.

METHODS:

Participants aged ≥18 years were recruited via an online panel in Europe, Japan and the USA to answer questions regarding skin disorders they may have experienced. Those reporting vitiligo (diagnosed or undiagnosed) or vitiligo signs (experiencing loss of skin colour but unaware of vitiligo and not diagnosed) were included in the analyses of vitiligo prevalence. Participants who self-reported physician-diagnosed vitiligo were given a broader survey to characterise disease progression, management and QoL (as measured with the Vitiligo-specific QoL [VitiQoL] instrument).

RESULTS:

The total estimated vitiligo prevalence among 35 694 survey participants (Europe, n = 18 785; USA, n = 8517; Japan, n = 8392) was 1.3% (diagnosed, 0.6%; undiagnosed, 0.4%; vitiligo signs, 0.3%). Among 219 patients formally diagnosed with vitiligo (Europe, n = 150; USA, n = 48; Japan, n = 21), total VitiQoL scores were associated with age (P = 0.00017), disease extent (P < 0.0001), disease progression (P < 0.0001), disease management (P < 0.0001) and time since diagnosis (P = 0.0015). Behaviour scores varied based on skin phototype (P = 0.024) and ethnicity (P = 0.048). Higher total VitiQoL scores were reported in patients with head lesions (P = 0.027) and those with head and hand and/or wrist lesions (P = 0.018). Substantial high concern (rated 8-10 on an 11-point Likert scale) for lesions was found across all body areas and varied with geographical region.

CONCLUSIONS:

The vitiligo prevalence rate may be higher than previously reported, with a substantial proportion attributed to people who have not received a formal diagnosis. Among formally diagnosed patients with vitiligo, QoL was most severely impacted by more progressive and higher extent of disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Vitiligo Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans País/Região como assunto: Asia Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Vitiligo Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans País/Região como assunto: Asia Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos